Spurned by AstraZeneca, is Pfizer out for GlaxoSmithKline?

The latest market chatter is that Pfizer ($PFE), rebuffed in its quest to acquire AstraZeneca ($AZN) last year, is taking a hard look at GlaxoSmithKline ($GSK), and one analyst says it might be a good idea. As Bloomberg notes, Deutsche Bank's Gregg Gilbert wrote in a note to investors that buying GlaxoSmithKline could solve some of Pfizer's tax woes by giving it a U.K. address, pointing to "a sense of urgency to create value by leveraging the power of its balance sheet to do needle-moving deals." Story | More from FiercePharma

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.